Compare EMO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMO | KROS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 851.8M | 655.9M |
| IPO Year | N/A | 2020 |
| Metric | EMO | KROS |
|---|---|---|
| Price | $44.38 | $21.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.20 |
| AVG Volume (30 Days) | 27.1K | ★ 857.8K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 6.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | N/A | ★ $246,718,000.00 |
| Revenue This Year | N/A | $6,924.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.56 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $26.42 | $9.12 |
| 52 Week High | $40.17 | $22.55 |
| Indicator | EMO | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 64.94 |
| Support Level | $43.94 | $19.76 |
| Resistance Level | $44.49 | $21.76 |
| Average True Range (ATR) | 0.65 | 0.90 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 34.51 | 57.35 |
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.